Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins

Mariko Tsukagoshi1,3, Kenichiro Araki1,3, Takehiko Yokobori4, Bolag Altan1, Hideki Suzuki1, Norio Kubo1,3, Akira Watanabe1,3, Norihiro Ishii1, Yasuo Hosouchi5, Masahiko Nishiyama4, Ken Shirabe2,3, Hiroyuki Kuwano1,3

1Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi Gunma 371-8511, Japan
2Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, Maebashi Gunma 371-8511, Japan
3Division of Hepatobiliary and Pancreatic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Maebashi Gunma 371-8511, Japan
4Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Maebashi Gunma 371-8511, Japan
5Department of Surgery and Laparoscopic Surgery, Gunma Prefecture Saiseikai-Maebashi Hospital, Maebashi Gunma 371-0821, Japan

Correspondence to: Hiroyuki Kuwano, email: hkuwano@gunma-u.ac.jp
Keywords: KPNA2, cholangiocarcinoma, gemcitabine, MRN complex, DNA repair
Received: August 10, 2016 Accepted: January 04, 2017 Published: February 02, 2017

ABSTRACT

Cholangiocarcinoma is a highly malignant tumor, and the development of new therapeutic strategies is critical. Karyopherin-α2 (KPNA2) functions as an adaptor that mediates nucleocytoplasmic transport. Specifically, KPNA2 transports one of the important DNA repair machineries, the MRE11-RAD50-NBS1 (MRN) complex, to the nucleus. In this study, we clarified the significance of KPNA2 in cholangiocarcinoma. KPNA2 expression evaluated by immunohistochemical analysis was common in malignant tissue but rare in adjacent noncancerous tissues. KPNA2 overexpression was significantly correlated with poor prognosis and was an independent prognostic factor after surgery. In patients with cholangiocarcinoma who received gemcitabine after surgery, KPNA2 overexpression tended to be a prognostic indicator of poor overall survival. In KPNA2-depleted cholangiocarcinoma cells, proliferation was significantly decreased and gemcitabine sensitivity was enhanced in vitro and in vivo. Expression of KPNA2 and the MRN complex displayed colocalization in the nucleus. In addition, nuclear localization of the MRN complex was regulated by KPNA2 in vitro. These results suggest that KPNA2 expression may be a useful prognostic and predictive marker of gemcitabine sensitivity and survival. The regulation of KPNA2 expression may be a new therapeutic strategy for cholangiocarcinoma.

INTRODUCTION

Cholangiocarcinoma is a malignant tumor originating from the bile duct epithelial cells that is classified as intrahepatic or extrahepatic depending on location [1, 2]. Although extrahepatic cholangiocarcinoma (EHCC) is relatively uncommon in Western countries, the incidence and mortality rate of cholangiocarcinoma continue to increase worldwide [3, 4]. In Japan in particular, it was reported that cholangiocarcinoma was responsible for approximately 12,000 deaths in 2013 [5]. Surgical resection is currently the only curative treatment for cholangiocarcinoma. However, the majority of patients are inoperable because most are diagnosed at an advanced stage [6–8]. Despite recent advances in surgical techniques and chemotherapy, the post-resection 5-year survival rate is only 20%–30% [9].
Gemcitabine (2’, 2’-difluoro-2’-deoxycytidine) is a nucleoside analog and a pyrimidine antimetabolite that is an effective agent for cholangiocarcinoma. The combination of gemcitabine and cisplatin is currently used as the standard of care for locally advanced or metastatic cholangiocarcinoma. However, overall survival and the therapeutic effect remain poor and insufficient [10]. To activate the cytotoxic actions of gemcitabine, cellular uptake and phosphorylation are required to modify gemcitabine to gemcitabine triphosphate (dFdCTP) [11, 12]. dFdCTP is incorporated into replicating DNA, which stalls the replication fork. Then, DNA damage response (DDR) proteins are activated, causing double-strand breaks (DSBs) that exert a cytotoxic effect by blocking DNA synthesis [13–15]. Thus, it is suggested that the nuclear localization of DDR proteins has an important role in gemcitabine sensitivity.

In general, the efficacy of DNA-damaging agents can be reduced by the activities of several DNA repair pathways [16]. First, the DDR histone (H2AX) and phosphoinositol kinase-like kinase [ataxia-telangiectasia mutated (ATM)] are phosphorylated and recruited to DNA DSBs induced by cytotoxic agents, including gemcitabine [17]. The MRE11-RAD50-NBS1 (MRN) complex plays important roles in recognizing and repairing such DNA DSBs. Thus, it is suggested that dysregulation of MRN complex-induced DNA repair contributes to gemcitabine resistance [14, 18]. In fact, it was reported that overexpression of the MRN complex promoted chemoresistance via enhanced DNA repair activity and also inhibited apoptosis [19]. Therefore, the DNA DSB repair machinery regulated by the MRN complex is a strong candidate target for cancer therapies against refractory diseases [16, 20].

The MRN complex may also function during DNA replication in both normal and cancer cells [21, 22]. It has been demonstrated that knockout of any component of the MRN complex causes early embryonic lethality in mice [23–25]. Thus, we focused on karyopherin-α2 (KPNA2), which participates in the nuclear transport of the MRN complex and which is specifically expressed in cancer cells and embryonic stem cells, but not in most normal cells [26, 27]. KPNA2 in cancer cells delivers numerous cargo proteins via nuclear localization signals to the nucleus including the DNA repair-associated MRN complex and proliferation-related protein c-Myc/E2F [28–30]. Moreover, a recent study reported that KPNA2 expression was also associated with the subcellular localization of DDR proteins, such as BRCA1 and RAD51, in breast cancer [18].

Recently, KPNA2 has emerged as a potential biomarker in several cancers [26, 31–38]. Our previous studies identified that high KPNA2 expression was correlated with poor prognosis and cancer progression in esophageal squamous cell carcinoma [35], gastric carcinoma [31], and colorectal carcinoma [39]. Moreover, the KPNA2 suppression strategy induced apoptosis and conferred anti-proliferation activity in several cancer cells [34]. However, the clinical significance of cancer-specific KPNA2 expression and the relationship with the MRN complex and gemcitabine sensitivity in cholangiocarcinoma remain unclear.

The purpose of this study was to identify the function and clinical significance of KPNA2 in cholangiocarcinoma. KPNA2 expression in cholangiocarcinoma tissues was investigated using immunohistochemical analysis to determine whether KPNA2 expression can serve as a prognostic marker of cholangiocarcinoma. Moreover, KPNA2 suppression analysis was performed in vitro and in vivo to clarify whether KPNA2 may play important roles in proliferation and gemcitabine sensitivity via nuclear translocation of the MRN complex. Our data clarified the significance of KPNA2 expression in clinical cholangiocarcinoma samples and highlighted the possibility of overcoming gemcitabine resistance by targeting KPNA2 in cholangiocarcinoma cells in vitro and in vivo for the first time.

**RESULTS**

**Immunohistochemical expression of KPNA2 in cholangiocarcinoma samples**

KPNA2 expression was higher in the nucleus than in the cytoplasm and higher in malignant tissue than in adjacent noncancerous tissues (Figure 1A). Nuclear KPNA2 expression levels were greater in marginal regions than in central regions (Figure 1B). The MRN complex, which contains representative KPNA2 cargo proteins, was expressed in both noncancerous and cancer tissues (Supplementary Figure 2). Of the 103 patients with cholangiocarcinoma, low KPNA2 expression was found in 23 (22.3%) patients and high expression in 80 (77.7%) (Figure 1C and 1D).

**Association between KPNA2 expression and clinicopathological characteristics**

The relationships between clinicopathological parameters and KPNA2 expression in 103 cholangiocarcinoma samples are presented in Table 1. High expression levels of KPNA2 were tightly associated with recurrence in 103 patients with cholangiocarcinoma ($P = 0.024$). There were no significant differences in age, sex, histological type, T factor, tumor size, lymph node metastasis, vascular invasion, perineural invasion, and TNM stage between patients with high and low KPNA2 expression.

The relationships between clinicopathological parameters and KPNA2 expression in EHCC or IHCC samples are presented in Supplementary Table 1. KPNA2 expression was also associated with the subcellular localization of DDR proteins, such as BRCA1 and RAD51, in breast cancer [18].

The purpose of this study was to identify the function and clinical significance of KPNA2 in cholangiocarcinoma. KPNA2 expression in cholangiocarcinoma tissues was investigated using immunohistochemical analysis to determine whether KPNA2 expression can serve as a prognostic marker of cholangiocarcinoma. Moreover, KPNA2 suppression analysis was performed in vitro and in vivo to clarify whether KPNA2 may play important roles in proliferation and gemcitabine sensitivity via nuclear translocation of the MRN complex. Our data clarified the significance of KPNA2 expression in clinical cholangiocarcinoma samples and highlighted the possibility of overcoming gemcitabine resistance by targeting KPNA2 in cholangiocarcinoma cells in vitro and in vivo for the first time.
expression in EHCC was significantly associated with venous invasion and recurrence ($P = 0.046$ and $P = 0.025$, respectively). High KPNA2 expression in IHCC was associated with lymph node metastasis ($P = 0.034$).

**Association between KPNA2 expression and prognosis**

The prognostic significance of KPNA2 expression is shown (Figure 2). Patients with high KPNA2 expression exhibited significantly shorter overall survival than those with low KPNA2 expression ($P = 0.001$; Figure 2A). Moreover, KPNA2 overexpression was significantly associated with cancer-specific and relapse-free survival ($P = 0.02$ and $P = 0.0001$, respectively; Figure 2B and 2C).

Next, the potential predictive role of KPNA2 expression during postoperative chemotherapy with gemcitabine was examined. In 16 patients with cholangiocarcinoma who received gemcitabine as an adjuvant chemotherapy, there was no significant difference in relapse-free survival ($P = 0.91$; Figure 2D) or overall survival ($P = 0.14$; Figure 2E) according to KPNA2 expression. In 32 patients with cholangiocarcinoma who received gemcitabine as an adjuvant chemotherapy or to treat recurrence, although KPNA2 overexpression tended to be a prognostic indicator of poor overall survival, there were no statistically significant differences ($P = 0.06$; Figure 2F).

**Univariate and multivariate analysis of clinicopathological factors associated with overall survival in patients with cholangiocarcinoma**

Univariate analysis of 103 patients with cholangiocarcinoma revealed that histological type ($P = 0.015$), lymph node metastasis ($P = 0.035$), vascular invasion ($P = 0.0001$), perineural invasion ($P = 0.017$), and KPNA2 expression ($P = 0.0004$) were significantly associated with overall survival in patients with cholangiocarcinoma.
associated with overall survival. Multivariate analysis revealed that vascular invasion, perineural invasion, and KPNA2 expression [risk ratio (RR) = 3.15; 95% confidence interval (CI) = 1.51–7.54; \( P = 0.001 \)] were independent predictors of poor survival (Table 2). Moreover, KPNA2 overexpression was an independent prognostic indicator of poor survival in 87 patients with EHCC (Supplementary Table 2), and it was significantly associated with overall survival in 16 patients with IHCC (Supplementary Table 4).

Table 1: Characteristics of patients with cholangiocarcinoma

| Variables                        | KPNA2 expression | \( P \) |
|----------------------------------|------------------|--------|
|                                  | Low (\( N = 23 \)) | High (\( N = 80 \)) |
| Mean age, y ± SD                 | 66.9 ± 9.0       | 68.5 ± 8.9 | 0.513 |
| Sex, \( n \) (%)                 |                  |        |
| Male                             | 14 (61)          | 56 (70)    | 0.414 |
| Female                           | 9 (39)           | 24 (30)    |       |
| Histological type, \( n \) (%)  |                  |        |
| Well, Moderately                 | 19 (83)          | 56 (70)    | 0.215 |
| Poor                             | 4 (17)           | 24 (30)    |       |
| T factor (UICC), \( n \) (%)    |                  |        |
| T1, 2                            | 15 (65)          | 39 (49)    | 0.160 |
| T3, 4                            | 8 (35)           | 41 (51)    |       |
| Tumor size, \( n \) (%)          |                  |        |
| <30 mm                           | 11 (48)          | 38 (48)    | 0.978 |
| ≥30 mm                           | 12 (52)          | 42 (52)    |       |
| Lymph node metastasis, \( n \) (%)|                 |        |
| Absent                           | 18 (78)          | 46 (58)    | 0.062 |
| Present                          | 5 (22)           | 34 (42)    |       |
| Vascular invasion, \( n \) (%)  |                  |        |
| Absent                           | 18 (78)          | 48 (60)    | 0.098 |
| Present                          | 5 (22)           | 32 (40)    |       |
| Perineural invasion, \( n \) (%)|                  |        |
| Absent                           | 11 (48)          | 39 (49)    | 0.938 |
| Present                          | 12 (52)          | 41 (51)    |       |
| TNM stage (UICC), \( n \) (%)   |                  |        |
| I-II                             | 19 (83)          | 67 (84)    | 0.897 |
| III-IV                           | 4 (17)           | 13 (16)    |       |
| Recurrence, \( n \) (%)         |                  |        |
| Absent                           | 15 (65)          | 31 (39)    | 0.024*|
| Present                          | 8 (35)           | 49 (61)    |       |

Abbreviations: UICC, Union for International Cancer Control; JSHBPS, Japanese Society of Hepato-Biliary-Pancreatic Surgery. * = \( P < 0.05 \).
KPNA2-specific siRNA inhibits tumor cell proliferation and enhances gemcitabine sensitivity in vitro

KPNA2 was highly expressed in TFK1 and HuCCT1 cells. Both KPNA2-specific siRNAs significantly reduced KPNA2 levels, as compared with control siRNA (Figure 3A). The proliferation of KPNA2-depleted cells was significantly lower than that of parent and negative control-transfected TFK1 and HuCCT1 cells (Figure 3B). Gemcitabine sensitivity was enhanced in KPNA2 siRNA-treated cells compared with control TFK1 and HuCCT1 cells (Figure 3C).

KPNA2-specific siRNA inhibits tumor cell proliferation and enhances gemcitabine sensitivity in vivo

Mice with xenografted cholangiocarcinoma tumors were treated with KPNA2 siRNA and/or gemcitabine. The volume of tumors injected with KPNA2 siRNA significantly decreased compared with that of control

Figure 2: Kaplan–Meier plots showing overall and disease-free survival according to karyopherin-α2 (KPNA2) expression. A. Among 103 patients with cholangiocarcinoma, overall survival was significantly shorter ($P = 0.001$) among those with high KPNA2 than those with low expression. B, C. High KPNA2 expression was significantly associated with shorter cancer-specific survival ($P = 0.02$) and relapse-free survival ($P = 0.0001$). D, E. In 16 patients with cholangiocarcinoma who received gemcitabine as adjuvant chemotherapy after surgical resection, there was no significant difference in relapse-free survival ($P = 0.91$) and overall survival ($P = 0.14$) between those with high and low KPNA2 expression. F. In 32 patients with cholangiocarcinoma who received gemcitabine after surgery or recurrence, KPNA2 overexpression tended to be a prognostic indicator of poor overall survival, although there were no significant differences ($P = 0.06$).
tumors (Figure 3D). The volume of gemcitabine-treated tumors injected with KPNA2 siRNA significantly decreased, as compared with tumors treated with only gemcitabine (Figure 3D). The tumor growth rate was measured and calculated at each time point (Figure 3E). In the control group, the tumor volume significantly increased after 3 weeks. On the contrary, tumor growth decreased in mice treated with KPNA2 siRNA. Moreover, tumor growth was further decreased in mice treated with KPNA2 siRNA and gemcitabine compared with that in mice treated with gemcitabine or KPNA2 siRNA only.

Expression of KPNA2 and the MRN complex in TFK1 cells and clinical cholangiocarcinoma tissues

Protein expression of the MRN complex was decreased in the nuclei of KPNA2-depleted cells. By contrast, protein expression in the cytoplasm was increased in both MRE11 and RAD50 cells (Figure 4A). Immunocytochemical analysis illustrated that expression of MRE11, RAD50, and NBS1 was mainly localized to the nucleus, and these proteins were colocalized with KPNA2 in control cells. As observed in Western blot analysis of KPNA2 siRNA-treated cells, expression of the MRN complex was decreased in the nucleus and increased in the cytoplasm (Figure 4B). Moreover, colocalization of KPNA2 and the MRN complex was observed in the nuclei of cells in clinical cholangiocarcinoma tissues (Figure 4C).

DISCUSSION

In this study, overexpression of nuclear KPNA2 was significantly associated with poor prognosis and chemosensitivity of cholangiocarcinoma. KPNA2 overexpression was an independent prognostic factor of overall and relapse-free survival. Depletion of KPNA2 decreased the viability of gemcitabine-treated cholangiocarcinoma cells in vitro and in vivo. Expression of the MRN complex was colocalized with that of KPNA2 in both cholangiocarcinoma tissues and cell lines. These findings clarified a new regulatory mechanism of gemcitabine sensitivity in cholangiocarcinoma by targeting the nuclear–cytoplasmic transportation of the MRN complex via KPNA2.

KPNA2 overexpression has been reported in several malignant tumors [26]. Several studies revealed that high KPNA2 expression is associated with cancer progression and poor prognosis [31, 33, 35, 38, 41–46], suggesting KPNA2 as a potential prognostic marker. In the current study, nuclear KPNA2 expression exhibited a significant association with poor prognosis in cholangiocarcinoma. Furthermore, a significant correlation was observed between high KPNA2 expression and shorter overall survival and relapse-free survival in patients with EHCC and IHCC. The significance of KPNA2 expression in cholangiocarcinoma is assumed to be consistent with the findings of previous reports. The present study results indicated that KPNA2 expression may be an independent prognostic marker of cholangiocarcinoma.

Several studies have reported that KPNA2 plays important roles in cell proliferation [33, 37] and that KPNA2 overexpression is associated with increased cell proliferation, while depletion of KPNA2 inhibits proliferation and increased apoptosis [31, 34]. In the present study, siRNA approaches were employed for KPNA2 functional analysis in vitro and in vivo because KPNA2 was expressed in all cholangiocarcinoma, gastric cancer, and colon cancer cell lines in our department, and an association between KPNA2 suppression and cell proliferation was noted in cholangiocarcinoma cells. KPNA2 is an adapter protein that mediates the...
Figure 3: *In vitro* and *in vivo* analysis of karyopherin-α2 (KPNA2) function in cholangiocarcinoma cell lines transfected with KPNA2-specific siRNAs. **A.** KPNA2-specific siRNA1 and siRNA2 significantly reduced KPNA2 expression compared with control siRNA in both TFK1 and HuCCT1 cells. **B.** Proliferation of TFK1 and HuCCT1 cells transfected with KPNA2-specific siRNAs was analyzed using the WST assay. The proliferation of KPNA2-depleted cells was significantly lower than that of parent and negative control (N-C)-transfected cells. *P* < 0.05 vs. N-C transfected cells. **C.** Proliferation and gemcitabine sensitivity of TFK1 and HuCCT1 cells transfected with KPNA2 siRNAs were analyzed using the WST assay. Gemcitabine sensitivity in KPNA2 siRNA-treated cells was enhanced compared with that in control cells for both TFK1 and HuCCT1 cells. *P* < 0.05 vs. N-C transfected cells. **D.** Representative pictures of subcutaneous TFK1-xenograft tumors after 3 weeks of gemcitabine treatment. KPNA2 siRNA (siRNA group and gemcitabine + siRNA group) and phosphate-buffered saline (PBS) (control group and gemcitabine group) were injected into tumors of the right and left flanks, respectively. Scale bar, 5 mm. **E.** The tumor growth curve of gemcitabine-treated TFK1-xenograft tumors with or without KPNA2 siRNA local injection. *P* < 0.05 siRNA group, the gemcitabine group vs. control group. **P** < 0.05, the gemcitabine + siRNA group vs. siRNA group, gemcitabine group.
Figure 4: Karyopherin-α2 (KPNA2) and MRE11-RAD50-NBS1 (MRN) complex expression in cholangiocarcinoma cell lines and tissues. A. TFK1 cells were transfected with KPNA2-specific siRNA, and the protein expression of KPNA2 and the MRN complex in both the nucleus and cytoplasm was analyzed using Western blotting. β-actin was used as a loading control. B. Intracellular localization of KPNA2 and the MRN complex in TFK1 cells treated with KPNA2 or control siRNA. TFK1 cells were immunostained with antibodies against KPNA2 (green) and MRE11, RAD50, and NBS1 (red). All sections were counterstained with 4′, 6-diamidino-2-phenylindole (DAPI, blue). Original magnification: ×600; scale bar, 20 μm. C. Intracellular localization of KPNA2 and the MRN complex in clinical cholangiocarcinoma tissue. Representative cholangiocarcinoma tissue was immunostained with antibodies against KPNA2 (green) and MRE11, RAD50, and NBS1 (red). All sections were counterstained with DAPI (blue). Original magnification: ×400; scale bar, 100 μm.
nuclear import of various proteins associated with cancer proliferation. Previous reports demonstrated that cell cycle-related transcription factors, such as E2F and c-Myc, were transferred from the cytoplasm to the nucleus by KPNA2 [44, 47]. These transcription factors may be involved in the molecular mechanism underlying reduced proliferation upon KPNA2 depletion in cholangiocarcinoma. Our results suggest a critical role of KPNA2 in the proliferation of cholangiocarcinoma cells.

In the present study, KPNA2 was significantly associated with survival, despite the fact that there were no correlations with the well-known prognostic factors, i.e., histological type and lymph node metastasis. On the other hand, low KPNA2 expression tended to be associated with a favorable outcome of gemcitabine treatment. In addition, gemcitabine sensitivity was enhanced in KPNA2-depleted cells in vitro and in vivo. Gemcitabine is a pyrimidine nucleoside analog that exhibits cytotoxic activity only after entry into the cell and phosphorylation [48]. dFdCTP is incorporated into DNA and causes stalling of replication forks and DNA DSBs [13–15]. The DNA repair mechanisms for the removal of nucleotide analogs from DNA are currently not well understood. Ewald et al. investigated the role of the MRN complex and ATM in response to stalled replication forks caused by gemcitabine and found that ATM, MRE11, and RAD50, but not NBS1 or H2AX, contributed to cell survival and recovery from gemcitabine-induced replication fork stalling [14]. DNA repair mechanisms are generally considered strong targets in cancer therapy [16, 20]. However, the MRN complex also plays an important role in normal DNA replication [21, 22]. In the present study, KPNA2 expression was high in malignant tissues, but rare in adjacent normal tissues. In contrast, MRN complex expression was high in both normal and cancer tissues (Supplementary Figure 2). These data clearly illustrated that the MRN complex was colocalized with KPNA2 in cholangiocarcinoma cells, but not in the surrounding normal cells (Figure 4C). Moreover, the nuclear–cytoplasmic transportation of the MRN complex could be regulated using KPNA2 siRNAs. These data suggest that targeting cancer-specific KPNA2 and not directly targeting the MRN complex, which is expressed in normal cells, may suppress the DNA repair pathways mediated by the MRN complex, thereby enhancing gemcitabine sensitivity and improving prognosis of cholangiocarcinoma.

In conclusion, the results of this study demonstrated that KPNA2 expression was significantly associated with poor prognosis in patients with cholangiocarcinoma. In addition, KPNA2 regulated cell proliferation and gemcitabine sensitivity in vitro and in vivo. Furthermore, expression of the MRN complex was colocalized with that of KPNA2 in both cholangiocarcinoma tissues and cell lines, and cellular localization of the MRN complex was controlled by KPNA2 regulation. The nuclear MRN complex, which is transferred by KPNA2, has an important role in gemcitabine sensitivity. These results suggest that KPNA2 may be a useful prognostic marker and an effective therapeutic target for cholangiocarcinoma.

MATERIALS AND METHODS

Patients and samples

The 103 surgically resected cholangiocarcinoma samples [87 EHCC and 16 intrahepatic cholangiocarcinoma (IHCC)] were obtained from patients who underwent surgical treatment at the Department of General Surgical Science, Gunma University Hospital, and Saiseikai Maebashi Hospital between 1995 and 2011. No patient received chemotherapy or irradiation prior to surgery. In 18 cases, there was a microscopic tumor at the cutting margin (R1-resection). Of 54 patients (52%) who received adjuvant chemotherapy, 13 received gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN, USA), 23 received S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan); 3 received gemcitabine + S-1, and 15 received tegafur–uracil (Taiho Pharmaceutical). Six patients (6%) received adjuvant irradiation. A total of 32 patients with cholangiocarcinoma received gemcitabine as adjuvant chemotherapy or to treat recurrence. All clinical samples were used in accordance with institutional guidelines and the Helsinki Declaration after obtaining written informed consent from all participants. Tumor stages were classified according to the seventh tumor-node-metastasis (TNM) classification of the Union for International Cancer Control (UICC) and the sixth Classification of Biliary Tract Carcinoma of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Clinicopathological findings were based on clinical records and pathology reports.

Immunohistochemical analysis

The resected surgical specimens were fixed with 10% formaldehyde, embedded in paraffin blocks, cut into 3-μm-thick sections, and mounted onto glass slides. All sections were incubated at 60°C for 60 min, deparaffinized in xylene, rehydrated, and incubated with fresh 0.3% hydrogen peroxide in 100% methanol for 30 min at room temperature to block endogenous peroxidase activity. After rehydration with a graded series of ethanol, the sections were then heated in boiled water and Immunosaver (Nisshin EM, Tokyo, Japan) at 98°C for 45 min. Nonspecific binding sites were blocked by incubation with Protein Block Serum-Free (DAKO, Carpinteria, CA, USA) for 30 min. The sections were then incubated with rabbit anti-KPNA2 polyclonal antibody (1:400; ab84440, anti-KPNA2 antibody, Abcam, Cambridge, England), anti-MRE11 rabbit monoclonal antibody (1:400; ab109623, anti-Mre11 antibody, Abcam), anti-RAD50 mouse monoclonal antibody (1:400; ab89, anti-Rad50 antibody,
Abcam), or anti-p95 NBS1 rabbit monoclonal antibody (1:400; ab32074, anti-p95 NBS1 antibody, Abcam) in Can Get Signal® immunostain (Toyobo Co., Ltd., Osaka, Japan) overnight at 4°C and at room temperature for 30 min. The sections were washed in phosphate-buffered saline (PBS) and incubated with Histofine Simple Stain MAX-PO (MULTI) (Nichirei Co., Tokyo, Japan) for 45 min at room temperature.

The chromogen 3,3′-diaminobenzidine tetrahydrochloride was applied as a 0.02% solution containing 0.005% \( \text{H}_2\text{O}_2 \) in 50 nM ammonium acetate–citrate acid buffer (pH 6.0). The sections were lightly counterstained with Mayer’s hematoxylin and mounted. No detectable staining was evident of negative controls established by omitting the primary antibody. Gastric cancer samples, which were regarded to have high-level expression in a previous study [31], were used as positive controls.

**Evaluation of immunostaining**

Immunohistochemical staining results for KPNA2 were evaluated as previously described [31]. Immunohistochemical slides were scanned and evaluated by two independent researchers in a blinded manner. The intensity of nuclear KPNA2 staining was scored as follows: 0, no staining; 1+, weak staining; 2+, moderate staining; and 3+, strong staining. The percentage of cells with nuclear staining was calculated by examining at least 1,000 cancer cells in five representative areas. The nuclear KPNA2 staining percentages were scored as follows: 0, no staining; 1+, 1%–10%; 2+, 11%–50%; and 3+, 51%–100%. The score was defined as the percentages multiplied by the intensity score (0, 1+, 2+, 3+, 6+, or 9+) (Supplementary Figure 1). The cut-off point was defined as follows: scores of 0–3 were considered to indicate low expression, whereas scores of 4, 6, and 9 indicated high expression.

**Cell culture**

The human cholangiocarcinoma cell lines TFK1 and HuCCT1 were obtained from RIKEN BRC (Biological Resource Center) through the National Bio-Resource Project of the MEXT, Japan, in 2008. TFK1 and HuCCT1 cell lines were authenticated by short tandem repeat DNA profiling by BEX Co., Ltd. (Tokyo, Japan) in 2015. These cells were cultured in RPMI 1640 medium (Wako, Osaka, Japan) containing 10% Fetal Bovine Serum (FBS) and supplemented with 100 U/ml of penicillin and streptomycin sulfate (Invitrogen, Carlsbad, CA, USA). Cells were maintained at 37°C in a humidified 5% CO\(_2\) incubator and collected with TrypLE™ Express Cell Dissociation Enzyme (Thermo Fisher Scientific, Kanagawa, Japan).

**In vitro transfection of KPNA2-specific siRNA**

KPNA2-specific siRNAs (siRNA 1: ACCUCUGGGGCCAUUUCCUACCUUA, UAAGGUAGAAAUAGCCACAGGAGGU, siRNA 2: CAGAUCUCUGGGCCAUUUCCUA, UAGGAAAUAGCCACAGGUACUG) and negative-control siRNA were purchased from GeneDesign, Inc. (Osaka, Japan). TFK1 and HuCCT1 cells were transfected with control or KPNA2-specific siRNA using Lipofectamine RNAiMAX regents (Invitrogen) according to the manufacturer’s recommendation. One day before transfection, TFK1 and HuCCT1 cells were seeded at 2 × 10\(^5\) cells/well in 2 ml of medium (RPMI 1640 with 10% FBS and 1% antibiotic) in 6-well flat-bottomed plates. After 24 h of incubation, cells were washed twice with PBS and Opti-MEM I Reduced Serum Medium (Invitrogen). The complexes of KPNA2 siRNA and Lipofectamine RNAiMAX (1 ml) were added to each well containing cells. After 6 h of incubation, 1 ml each of 20% FBS and antibiotic-free RPMI 1640 were added to each well. The cells were transfected with KPNA2 siRNAs again at 96 h of incubation after the first transfection to strongly silence KPNA2 protein expression as previously described [34].

**Protein extraction and western blot analysis**

Western blot analysis was used to confirm KPNA2 protein expression in cholangiocarcinoma cell lines. Total proteins, nucleoproteins, and cytoplasmic proteins were extracted from TFK1 and HuCCT1 cells using the PRO-PREP Protein Extraction Solution Kit (iNtRON Biotechnology, Sungnam, Kyungki-Do, Korea) and the NE-PER Nuclear and Cytoplasmatic Extraction Kit (Thermo Scientific). The proteins were separated using SDS–PAGE with 10% Bis–Tris gels and transferred to membranes. The membranes were blocked with 5% skim milk and incubated overnight at 4°C with anti-KPNA2 rabbit polyclonal antibody (1:1000; Abcam), anti-MRE11 rabbit monoclonal antibody (1:2000; Abcam), anti-RAD50 mouse monoclonal antibody (1:2000; Abcam), anti-p95 NBS1 rabbit monoclonal antibody (1:2000; Abcam), GAPDH antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or anti-β-actin mouse monoclonal antibody (1:1000; clone AC-74; Sigma, St. Louis, MO, USA). The membranes were then treated with horseradish peroxidase (HRP)-conjugated secondary antibodies. Specific signals were detected using the ECL Prime Western Blotting Detection System (GE Healthcare, Tokyo, Japan) and quantified using an Image Quant LAS 4000 instrument (GE Healthcare).

**In vitro proliferation assay**

Cell proliferation analysis of siRNA-transfected cultures was performed using TFK1 and HuCCT1 cells.
These cells were cultured in 96-well culture plates, at 10,000 cells/well, in 100 μl of medium. After initial cell seeding, cell viability was analyzed using the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). Evaluations were performed after 0, 24, 48, 72, and 96 h. The cell counting solution was added at a concentration of 10 μl/well, and cells were incubated at 37°C in a humidified 5% CO₂ atmosphere for 2 h 30 min. The optical density of the wells was measured at 450 nm using an xMark™ Microplate Absorbance Spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA). All results were derived from 12 sets of duplicated experiments.

Gemcitabine sensitivity assay

TFK1 and HuCCT1 cells transfected with KPNA2 siRNAs were dispensed into 96-well plates. Twenty-four hours after the initial seeding, gemcitabine was added at a final concentration of 10 μM. Evaluations were performed after 0, 48, 72, 96, and 120 h. To quantitate cell viability using the Cell Counting Kit-8 (Dojindo Laboratories), 10 μl/well of the cell counting solution was added and the plates were incubated at 37°C in a humidified 5% CO₂ atmosphere for 2 h 30 min. The optical density of the wells was measured at 450 nm using an xMarkTM Microplate Absorbance Spectrophotometer. All results were derived from 12 sets of duplicated experiments.

Xenograft mouse models

Mouse experiments were performed in compliance with the guidelines of the Institute for Laboratory Animal Research at Gunma University, Maebashi, Japan. In total, a TFK1 cell suspension (3 × 10⁶ cells in 200 μl of PBS) was subcutaneously (s.c.) injected into the bilateral flanks of 8-week-old female NOD-SCID mice (CLEA Japan, Inc, Tokyo, Japan).

Treatment with KPNA2 siRNA and gemcitabine in vivo

Mice with s.c. xenografted tumors were treated with KPNA2 siRNA and/or gemcitabine when the tumor reached a maximum diameter of 5 mm. Mice were randomized into four groups as follows: group A, control; group B, KPNA2 siRNA alone; group C, gemcitabine alone; and group D, KPNA2 siRNA + gemcitabine. Each group contained three mice (n = 3).

In vivo silencing of KPNA2 was performed as described by Takei et al [40]. Mice were deeply anesthetized with pentobarbital (40 mg/kg intraperitoneal injection). A fork-type electrode was inserted into the tumor, scooping from the bottom of the tumor, and then KPNA2 siRNA (2000 pmol/100 μl) or PBS (100 μl) was injected into each. Immediately, the plate-type electrode was put in contact with the surface of the tumor and electric pulses were delivered to each tumor using the CUY21EDIT II Next-Generation Electroporator (Bex, Japan). In groups A and C, PBS was injected into tumors in the bilateral flanks. In group B and D, KPNA2 siRNA was injected into tumors of the right flanks and PBS was injected into tumors of the left flanks. After injection of the siRNA and electroporation, gemcitabine was administered via intraperitoneal injection as follows: group A and B, 400 μl of PBS; and groups C and D, 1 mg gemcitabine/PBS 200 μl/10 g mouse body weight. The body weights of the mice were measured every other day (Supplementary Figure 3). Tumor diameters were measured every other day and calculated using the following formula: tumor volume = S × S × L/2, where S is the short diameter of the tumor in millimeters and L is the maximum diameter of the tumor in millimeters. Therapy was repeated every 5 days for 3 weeks. The mice were then sacrificed and the tumors were removed. These xenografted tumor formations were microscopically validated after hematoxylin and eosin staining.

Fluorescent immunocytochemistry

Immunofluorescence of KPNA2 siRNA-transfected cultures of TFK1 cells was performed. Forty-eight hours after transfection according to the aforementioned method, the cells were fixed with 4% paraformaldehyde for 20 min at room temperature and then incubated with PBS containing 0.01% Triton X-100 for 15 min at room temperature. After inhibiting endogenous peroxidase activity, nonspecific binding sites were blocked with TNT (Tris-NaCl-Tween) blocking buffer for 30 min. This was followed by incubation with primary antibodies against KPNA2 (1:400) for 1 h at room temperature. The sections were then rinsed in TNT buffer three times for 5 min each and incubated for 30 min at room temperature with HRP-conjugated secondary antibody. After washing with TNT buffer three times for 5 min each, fluorescein with the tyramide signal amplification (TSA) method (Opal™ 3-Plex Kit; Perkin Elmer, Waltham, MA, USA) was applied to the tissue section for 10 min. The sections were then washed in TNT buffer three times for 5 min each, and the secondary detection reagents were added via similar methods [Cy3-conjugated streptavidin; secondary antibodies: MRE11 (1:800), RAD50 (1:800), and NBS1 (1:800)]. All sections were counterstained with 4′, 6-diamidino-2-phenylindole (DAPI) and examined under an All-in-One BZ-X710 fluorescence microscope (Keyence Corporation).

Fluorescent immunohistochemical analysis

The resected surgical cholangiocarcinoma specimens were fixed using 10% formaldehyde, embedded in paraffin blocks, cut into 3-μm-thick sections, and mounted onto glass slides. Fluorescent immunohistochemical analysis
was performed using TSA methods according to the manufacturer’s protocol (Opal™ 3-Plex Kit). Following deparaffinization, endogenous peroxidase was inhibited by incubating sections in 0.3% H$_2$O$_2$ in methanol for 30 min. After washing in ethanol and PBS, the sections were boiled in citrate buffer (pH 6.4) for 15 min in a microwave. Nonspecific binding sites were blocked by incubation with TNT blocking buffer for 30 min and the sections were incubated with the primary antibodies against KPNA2 (1:600) for 1 h at room temperature. The sections were rinsed in TNT buffer three times for 5 min each and then incubated for 30 min at room temperature with HRP-conjugated secondary antibody. After washing with TNT buffer three times for 5 min each, fluorescein with TSA methods (Opal™ 3-Plex Kit) was applied to the tissue section for 10 min. The sections were then washed in TNT buffer three times for 5 min each and the application of secondary detection reagents was performed using similar methods [Cy3-conjugated streptavidin; secondary antibodies: MRE11 (1:800), RAD50 (1:800), and NBS1 (1:800)]. All sections were counterstained using DAPI and examined under an All-in-One BZ-X710 fluorescence microscope.

Statistical analysis

Statistical significance was analyzed using the Mann–Whitney U test or ANOVA for continuous variables and the chi-squared test or Fisher’s exact test for categorical variables. Survival curves were calculated using the Kaplan–Meier method. Differences between survival curves were analyzed using the log-rank test. Prognostic factors were examined by univariate and multivariate analyses using Cox’s proportional hazard model. Results were considered statistically significant when the relevant $P$ value was $<0.05$, and all statistical analyses were performed using JMP 11 software (SAS Institute, Cary, NC, USA).

ACKNOWLEDGMENTS

We wish to thank Dr. Kenji Kashiwabara for providing valuable cooperation and Ms. Kayoko Hashimoto for excellent assistance. We would like to thank Enago (www.enago.jp) for the English language review.

We thank the staff at Bioresource Center, Gunma University Graduate School of Medicine for technical help.

This work was carried out in part at Bioresource Center, Gunma University Graduate School of Medicine.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to disclose.

DISCLOSURE STATEMENT

Masahiko Nishiyama received a research grant from Yakult Honsha Co., Ltd.

GRANT SUPPORT

This work was supported in part by the following grants and foundations: Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS); grant numbers 26461969, 15K10129 and 15K10085. The work was supported in part by Uehara Zaidan, Medical Research Encouragement Prize of The Japan Medical Association, Promotion Plan for the Platform of Human Resource Development for Cancer and New Paradigms-Establishing Centers for Fostering Medical Researchers of the Future programs by Ministry of Education, Culture, Sports, Science and Technology of Japan, and Gunma University Initiative for Advanced Research (GIAR).

Authors’ contributions

Conception and design: M. Tsukagoshi, K. Araki, T. Yokobori, B. Altan, K. Shirabe, and H. Kuwano.

Development of methodology: T. Yokobori, B. Altan, A. Watanabe, K. Shirabe, and H. Kuwano.

Acquisition of data: M. Tsukagoshi, K. Araki, H. Suzuki, N. Kubo, A. Watanabe, N. Ishii, Y. Hosouchi, M. Nishiyama, K. Shirabe, and H. Kuwano.

Analysis and interpretation of data: M. Tsukagoshi, K. Araki, T. Yokobori, B. Altan, K. Shirabe, and H. Kuwano.

Composition, review, and/or revision of the manuscript: M. Tsukagoshi, K. Araki, T. Yokobori, K. Shirabe, and H. Kuwano.

Administrative, technical, or material support: H. Suzuki, Y. Hosouchi, M. Nishiyama, K. Shirabe, and H. Kuwano.

Study supervision: K. Shirabe and H. Kuwano.

All authors read and approved the final version of the manuscript.

REFERENCES

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. New Engl J Med. 1999; 341: 1368–78.
2. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224: 463-73; discussion 473–5.
3. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, Toledano MB. Rising trends in
cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012; 56: 848–54.

4. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC canc. 2002; 2: 10.

5. Vital Statistics of Japan. Vital, Health and Social Statistics Division, Statistics and Information Department, Minister’s Secretariat, Ministry of Health, Labor and Welfare 2013. http://www.mhlw.go.jp/english/database/db-hw/s01.html

6. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001; 5: 191–218.

7. Friman S. Cholangiocarcinoma—current treatment options. Scand J Surg. 2011; 100: 30–4.

8. Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Therapeut. 2006; 23: 1287–96.

9. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009; 208: 134–47.

10. Valle J, Wasan H, Palmer DH, Cunningham D, Anthony A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, A. B. C. Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med. 2010; 362: 1273–81.

11. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2’, 2’-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Canc Res. 1988; 48: 4024–31.

12. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006; 17:v7–12.

13. Jones RM, Kotsantis P, Stewart GS, Groth P, Petermann E. BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine. Mol Canc Therapeut. 2014; 13: 2412–21.

14. Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Canc Res. 2008; 68: 7947–55.

15. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 1995; 22: 19–25.

16. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Canc. 2008; 8: 193–204.

17. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Canc Therapeut. 2007; 6: 1239–48.

18. Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA. KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Br J Canc. 2015; 112: 1929–37.

19. Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, Jungreis D, Carney J, O’Malley BW Jr, Li D. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Investig. 2009; 119: 1974–85.

20. Gao R, Singh R, Kaul Z, Kaul SC, Wadhwa R. Targeting of DNA Damage Signaling Pathway Induced Senescence and Reduced Migration of Cancer cells. J Gerontol A Biol Sci Med Sci. 2015; 70: 701–13.

21. D’Amours D, Jackson SP. The Mre11 complex: at the crossroads of dna repair and checkpoint signaling. Nat Rev Mol Cell Biol. 2002; 3: 317–27.

22. Stracker TH, Theunissen JW, Morales M, Petrini JH. The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. DNA repair. 2004; 3: 845–54.

23. Buis J, Wu Y, Deng Y, Leddon J, Westfield G, Eckersdorff M, Sekiguchi JM, Chang S, Ferguson DO. Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation. Cell. 2008; 135: 85–96.

24. Luo G, Yao MS, Bender CF, Mills M, Bladl AR, Bradley A, Petrini JH. Disruption of mRad50 causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing radiation. Proc Natl Acad Sci Unit States Am. 1999; 96: 7376–81.

25. Zhu J, Petersen S, Tessarollo L, Nussenzweig A. Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr Biol. 2001; 11: 105–9.

26. Christiansen A, Dyrsjkot L. The functional role of the novel biomarker karyopherin alpha 2 (KPNA2) in cancer. Canc Lett. 2013; 331: 18–23.

27. Young JC, Major AT, Miyamoto Y, Loveland KL, Jans DA. Distinct effects of importin alpha2 and alpha4 on Oct3/4 localization and expression in mouse embryonic stem cells. Faseb J. 2011; 25: 3958–65.

28. Antoccia A, Kobayashi J, Tauchi H, Matsuura S, Komatsu K. Nijmegen breakage syndrome and functions of the responsible protein, NBS1. Genome Dyn. 2006; 1: 191–205.

29. Kutay U, Muhlhauser P. Cell biology: taking a turn into the crossroads of dna repair and checkpoint signaling. Nat Rev Canc. 2002; 3: 809–21.

30. Tseung SF, Chang CY, Wu KJ, Teng SC. Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1. J Biol Chem. 2005; 280: 39594–600.

31. Altan B, Yokobori T, Mochiki E, Ohno T, Ogata K, Ogawa A, Yanai M, Kobayashi T, Luvsandagva B, Asao T, Kuwano H. Nuclear karyopherin-alpha2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer. Carcinogenesis. 2013; 34: 2314–21.

32. Kelley JB, Talley AM, Spencer A, Gioeli D, Paschal BM. Karyopherin alpha7 (KPNA7), a divergent member of the
importin alpha family of nuclear import receptors. BMC Cell Biol. 2010; 11: 63.

33. Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstader F, Hartmann A, Jaggi R, Moch H, et al. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Canc Res. 2011; 17: 1111–21.

34. Noetzel E, Rose M, Bornemann J, Gajewski M, Knuchel R, Dahl E. Nuclear transport receptor karyopherin-alpha2 promotes malignant breast cancer phenotypes in vitro. Oncogene. 2012; 31: 2101–14.

35. Sakai M, Sohda M, Miyazaki T, Suzuki S, Sano A, Tanaka N, Inose T, Nakajima M, Kato H, Kuwano H. Significance of karyopherin-{alpha} 2 (KPNA2) expression in esophageal squamous cell carcinoma. Anticancer Res. 2010; 30: 851–6.

36. Teng SC, Wu KJ, Tseng SF, Wong CW, Kao L. Importin KPNA2, NBS1, DNA repair and tumorigenesis. J Mol Histol. 2006; 37: 293–9.

37. Umegaki N, Tamai K, Nakano H, Moritsugu R, Yamazaki T, Hanada K, Katayama I, Kaneda Y. Differential regulation of karyopherin alpha 2 expression by TGF-beta1 and IFN-gamma in normal human epidermal keratinocytes: evident contribution of KPNA2 for nuclear translocation of IRF-1. J Invest Dermatol. 2007; 127: 1456–64.

38. Wang CI, Wang CL, Wang CW, Chen CD, Wu CC, Liang Y, Tsai YH, Chang YS, Yu JS, Yu CJ. Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int J Canc. 2011; 128: 2364–72.

39. Takada T, Tsutsumi S, Takahashi R, Ohsone K, Tatsuki H, Suto T, Kato T, Fujii T, Yokobori T, Kuwano H. KPNA2 over-expression is a potential marker of prognosis and therapeutic sensitivity in colorectal cancer patients. J Surg Oncol. 2016; 113: 213–7.

40. Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsumu S, Muramatsu T, Kadomatsu K. In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Canc Therapeut. 2008; 7: 211–21.

41. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Durst M, Klinkhammer-Schalke M, Blaszky H, Knuechel R, Hartmann A, et al. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Canc Res. 2006; 12: 3950–60.

42. Gluz O, Wild P, Meiler R, Diao-Danbrock R, Ting E, Mohrmann S, Shuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, et al. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Canc. 2008; 123: 1433–8.

43. Grupp K, Habermann M, Sirta H, Simon R, Steurer S, Hue-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzler H, Wilczak W, Kluth M, et al. High nuclear karyopherin alpha 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Mod Pathol. 2014; 27: 96–106.

44. Huang L, Wang HY, Li JD, Wang JH, Zhou Y, Luo RZ, Yun JP, Zhang Y, Jia WH, Zheng M. KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a. Cell Death Dis. 2013; 4: e745.

45. Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, et al. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. J Pathol. 2014; 234: 239–52.

46. Li XL, Jia LL, Shi MM, Li X, Li ZH, Liu HY, Wang EH, Jia XS. Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression. J Transl Med. 2013; 11: 232.

47. Wang CI, Chien KY, Wang CL, Liu HP, Cheng CC, Chang YS, Yu JS, Yu CJ. Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer. Mol Cell Proteomics. 2012; 11: 1105–22.

48. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-cancer drugs. 1995; 6: 7–13.
Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins

SUPPLEMENTARY FIGURES AND TABLES

Supplementary Figure 1: Immunohistochemical expression of karyopherin-α2 (KPNA2) in cholangiocarcinoma tissues.
A. Positive KPNA2 expression was mainly localized to the nuclei of tumor cells. Nuclear KPNA2 expression was evaluated according to staining intensity and scored as follows: 0, no staining; 1+, weak staining; 2+, moderate staining; and 3+, strong staining. B, C, D. The nuclear KPNA2 staining percentages were scored as follows: 0, no staining; 1+, 1%–10% (B); 2+, 11%–50% (C); and 3+, 51%–100% (D). E. The score was defined as the percentage score multiplied by the intensity score. The cut-off point was defined as follows: grades 0–3 were considered low expression, whereas grades 4, 6, and 9 were considered high expression.
Supplementary Figure 2: Immunohistochemical expression of karyopherin-α2 (KPNA2) and the MRE11-RAD50-NBS1 (MRN) complex in a representative cholangiocarcinoma tissue including noncancerous cells. A. Positive KPNA2 expression was mainly restricted to cancer tissues (arrowhead), whereas it was rare in noncancerous tissues (arrow) (A). B, C, D. Representative KPNA2 cargo proteins MRE11 (B), RAD50 (C), and NBS1 (D) were expressed in both noncancerous (arrow) and cancer tissues (arrowhead).
Supplementary Figure 3: The relationship between mice body weight and treatments in the xenograft experiments. The body weights of the mice were measured every other day. There was no correlation between the body weight and treatments.
Supplementary Table 1: Characteristics of patients with extrahepatic cholangiocarcinoma and intrahepatic cholangiocarcinoma

See Supplementary File 1
Supplementary Table 2: Cox univariate/multivariate regression analysis of variables related to relapse-free survival in patients with cholangiocarcinoma

| Clinicopathological variables                  | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | RR  | 95% CI | P     | RR  | 95% CI | P     |
| Age (<65 vs. ≥65)                             | 0.85 | 0.55–1.34 | 0.472 | -   | -     | -     |
| Sex (male vs. female)                         | 0.62 | 0.37–1.00 | 0.052 | -   | -     | -     |
| Histological type (well, moderately vs. poor) | 1.89 | 1.14–3.05 | 0.015* | 1.50 | 0.89–2.45 | 0.123 |
| T factor (UICC) (T1, 2 vs. 3, 4)              | 1.73 | 1.12–2.70 | 0.014* | 1.62 | 1.02–2.57 | 0.041* |
| Lymph node metastasis (absent vs. present)    | 2.40 | 1.48–3.89 | 0.0005* | 2.09 | 1.27–3.46 | 0.004* |
| KPNA2 expression (low vs. high)               | 3.41 | 1.85–6.93 | <0.0001* | 3.29 | 1.77–6.75 | <0.0001* |

Abbreviations: RR, relative risk; CI, confidence interval; UICC, Union for International Cancer Control. * = P < 0.05.
Supplementary Table 3: Cox univariate/multivariate regression analysis of variables related to overall survival in patients with extrahepatic cholangiocarcinoma

| Clinicopathologic variable | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | RR  | 95% CI   | P | RR  | 95% CI   | P |
| Age (<65 vs. ≥65)          | 0.82| 0.48–1.40 | 0.465 | – | – | – |
| Gender (male vs. female)    | 0.81| 0.44–1.42 | 0.473 | – | – | – |
| Histology type (well, moderately vs. poor) | 2.18| 1.21–3.82 | 0.011* | 2.07| 1.11–3.76 | 0.023* |
| T factor (T1, 2 vs. 3, 4)  | 1.77| 1.04–3.07 | 0.037* | 1.05| 0.57–1.95 | 0.879 |
| Lymph node metastasis (absent vs. present) | 1.68| 0.96–2.91 | 0.069 | – | – | – |
| Lymphatic invasion (0, 1 vs. 2, 3) | 2.67| 1.49–4.79 | 0.001* | 2.14| 1.13–4.02 | 0.019* |
| Venous invasion (0, 1 vs. 2, 3) | 3.14| 1.75–5.60 | 0.0002* | 1.54| 0.78–3.06 | 0.211 |
| Perineural invasion (0, 1 vs. 2, 3) | 2.32| 1.24–4.73 | 0.007* | 2.03| 1.06–4.24 | 0.032* |
| KPNA2 expression (low vs. high) | 3.01| 1.37–7.98 | 0.004* | 2.64| 1.18–7.15 | 0.017* |

Abbreviations: RR, relative risk; CI, confidence interval. * = P-value < 0.05.
Supplementary Table 4: Cox Univariate regression analysis of variables related to overall survival in patients with intrahepatic cholangiocarcinoma

| Clinicopathologic variable                      | Univariate analysis |          |          |          |
|------------------------------------------------|---------------------|----------|----------|----------|
| Age (<65 vs. ≥65)                              | RR                  | 1.22     | 0.19–23.5| 0.851    |
| Gender (male vs. female)                       | RR                  | 0.78     | 0.14–4.27| 0.766    |
| Tumor size (<50mm vs. ≥50)                     | RR                  | 0.63     | 0.09–3.23| 0.583    |
| Vascular invasion (absent vs. present)         | RR                  | 3.77     | 0.70–28.21| 0.123   |
| T factor (T1, 2 vs. 3, 4)                      | RR                  | 0.45     | 0.02–2.93| 0.440    |
| Lymph node metastasis (absent vs. present)     | RR                  | 2.24     | 0.41–12.29| 0.334   |
| KPNA2 expression (low vs. high)                | RR                  | 8.13     | 1.26–158.32| 0.026*  |

Abbreviations: RR, relative risk; CI, confidence interval. * = P-value < 0.05.
Supplementary Table S1: Characteristics of patients with extrahepatic cholangiocarcinoma and intrahepatic cholangiocarcinoma

| Factors                              | Extrahepatic cholangiocarcinoma (N = 87) | Intrahepatic cholangiocarcinoma (N = 16) |
|--------------------------------------|------------------------------------------|-------------------------------------------|
|                                      | KPNA2 expression                          | KPNA2 expression                          |
|                                      | Low (N = 16)                              | High (N = 71)                             | Low (N = 7) | High (N = 9) | P   |
| Mean age, years ± SD                 | 65.1 ± 9.5                                | 68.4 ± 9.2                                | 70.9 ± 7.7  | 69.4 ± 6.9  | 0.228 |
| Sex, n (%)                           | 0.469                                     |                                          | 1.000       |              |      |
| Male                                 | 10 (63)                                   | 51 (72)                                   | 4 (57)      | 5 (56)      |      |
| Female                               | 6 (37)                                    | 20 (28)                                   | 3 (43)      | 4 (44)      |      |
| Histology type, n (%)                | 0.312                                     |                                          | 1.000       |              |      |
| Well, Moderately                     | 13 (81)                                   | 49 (69)                                   | 6 (86)      | 7 (78)      |      |
| Poor                                 | 3 (19)                                    | 22 (31)                                   | 1 (14)      | 2 (22)      |      |
| T factor (UICC), n (%)               | 0.084                                     |                                          | 0.302       |              |      |
| T1, 2                                | 11 (69)                                   | 32 (45)                                   | 3 (43)      | 7 (78)      |      |
| T3, 4                                | 5 (31)                                    | 39 (55)                                   | 4 (57)      | 2 (22)      |      |
| Lymph node metastasis, n (%)         | 0.472                                     |                                          | 0.034*      |              |      |
| Absent                               | 11 (69)                                   | 42 (59)                                   | 4 (57)      | 3 (33)      |      |
| Present                              | 5 (31)                                    | 29 (41)                                   | 3 (43)      | 6 (67)      |      |
| Lymphatic invasion (JSBPS), n (%)    | 0.683                                     |                                          | 0.596       |              |      |
| 0, 1                                 | 11 (69)                                   | 45 (63)                                   | 4 (57)      | 7 (78)      |      |
| 2, 3                                 | 5 (31)                                    | 26 (37)                                   | 3 (43)      | 2 (22)      |      |
| Venous invasion (JSBPS), n (%)       | 0.046*                                    |                                          |             |              |      |
| 0, 1                                 | 14 (88)                                   | 45 (63)                                   | 7 (100)     | 4 (44)      |      |
|                  | Present | 0  | 5 (56) |
|------------------|---------|----|--------|
| Perineural invasion (JSBPS), n (%) | 2 (12)  | 26 (37) |
| 0, 1             | 5 (31)  | 18 (25) |
| 2, 3             | 11 (69) | 53 (75) |
| TNM stage (UICC), n (%) |         |       | 0.634  |
| I, II            | 4 (57)  | 3 (33) |
| III, IV          | 3 (43)  | 6 (67) |
| Recurrence, n (%) |         |       | 0.025* |
| Absent           | 4 (57)  | 4 (44) |
| Present          | 3 (43)  | 5 (56) |

* = P < 0.05

Abbreviations: UICC, Union for International Cancer Control; JSBPS, Japanese Society of Hepato-Biliary-Pancreatic Surgery.